Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315)
:2315
Want to see HK:2315 full AI Analyst Report?
2315 Stock Chart & Stats
HK$28.70
-HK$0.07(-0.93%)
At close: 4:00 PM EST
HK$28.70
-HK$0.07(-0.93%)
Day’s Range― - ―
52-Week RangeHK$12.00 - HK$70.15
Previous CloseN/A
Volume49.50K
Average Volume (3M)488.12K
Market Cap
HK$19.77B
Enterprise ValueHK$15.92B
Total Cash (Recent Filing)HK$1.56B
Total Debt (Recent Filing)HK$584.09M
Price to Earnings (P/E)25.3
Beta1.12
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.43
Shares Outstanding110,781,920
10 Day Avg. Volume755,126
30 Day Avg. Volume488,121
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)5.83
Price to Sales (P/S)9.20
P/FCF Ratio44.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.73
Revenue Forecast (FY)HK$1.89B
Bulls Say, Bears Say
Bulls Say
Revenue Scale & Unit EconomicsMulti-year revenue scaling and persistently high gross margins indicate durable unit economics for Biocytogen's antibody discovery and preclinical services. A large revenue base and strong margins support reinvestment in platform R&D and make core services profitable across cycles, underpinning long-term cash generation if client demand remains stable.
Profitability InflectionThe structural move from multi-year losses to sustained profitability by 2024–2025 demonstrates operational leverage in the service/platform model. Persistent positive margins reduce dependence on external funding, improve internal R&D funding capacity, and increase resilience versus peers that remain loss-making, provided execution and revenue visibility continue.
Improved Cash GenerationMaterial improvement in operating cash flow and positive free cash flow shows the business now converts earnings into cash. Strong cash generation reduces refinancing risk, funds organic growth and platform investment, and provides optionality for partnerships or licensing, supporting financial durability over the medium term.
Bears Say
Earnings Volatility HistoryA recent history of multi-year losses highlights that profitability is newly achieved and could be cyclical. Biotech services and milestone-driven revenue are subject to client program timing and partnership cadence; a reversion to prior loss profiles remains a realistic risk unless revenue and margin trends sustain across multiple quarters.
Free Cash Flow DeclineAlthough FCF is positive, a meaningful year-over-year decline signals potential timing issues in cash receipts or rising operating/capital requirements. For a company moving from losses to profitability, falling FCF can constrain reinvestment or force financing if the trend continues, making cash conversion and consistency a key monitoring item.
Capital-structure VolatilityLarge year-to-year swings in leverage and equity levels suggest past reliance on financing and possible dilution or balance-sheet maneuvering common in biotechs. If clinical or partnership milestones slip, the company could face renewed financing needs or dilution, so sustained profitability and cash flow are required to lock in recent balance-sheet improvements.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H News
2315 FAQ
What was Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price range in the past 12 months?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H lowest stock price was HK$12.00 and its highest was HK$70.15 in the past 12 months.
What is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s market cap?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s market cap is HK$19.77B.
When is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s upcoming earnings report date?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s upcoming earnings report date is Sep 02, 2026 which is in 104 days.
How were Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s earnings last quarter?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H released its earnings results on Apr 27, 2026. The company reported HK$0.264 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.264.
Is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H overvalued?
According to Wall Street analysts Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price is currently Overvalued.
Does Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H pay dividends?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H does not currently pay dividends.
What is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s EPS estimate?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H have?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has 110,781,920 shares outstanding.
What happened to Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price movement after its last earnings report?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H reported an EPS of HK$0.264 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.917%.
Which hedge fund is a major shareholder of Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2315
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Company Description
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs worldwide. The company's pipeline includes 12 core products, among which two products are in Phase II multi-regional clinical trials and two products are in Phase I clinical trials. It focuses on developing drugs in the areas of oncology, autoimmune, inflammatory, metabolic, and other diseases. The company was founded in 2009 and is headquartered in Beijing, China. Beijing Biocytogen Co., Ltd. develops and prepares gene engineered animals to large-scale supply of animal models. It offers preclinical animal studies using gene humanized models, PDX models, and human immune system reconstruction models. The company's products include B-NDG mice, cre mouse models, cre rat models, B-p53 KO mice, B-ApoE KO mice, B-hIL6 mice, B-IL17-EGFP KI mice, B-TGFb1 cKO mice, genome- edited hESC, luciferase reported stable tumor cell lines, B-Pink1 KO rats, B-IL2rg KO rats, B-Cas9D10A cKI rats, B-ApoA4 KO rats, B-LDLR KO rats, B-Prkdc KO rats, B-Rag2 KO rats, B-tdTomato cKI rats, B-ApoE KO rats, B-hTnf mice, and B-hFcgrt (FcRn) mice. Beijing Biocytogen Co., Ltd. also develops antibody research and development platform and provides pharmacology services in the areas of tumor immunity, tumor and autoimmunity, and in vivo and in vitro pharmacology and pharmacology service platform. It also sells its products online. The company was founded in 2008 and is based in Beijing, China with additional locations in Beijing, Haimen, Jiangsu, Shanghai, China; Heidelberg, Germany; and Boston, the United States.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) Earnings & Revenues
Technical Analysis
Ascletis Pharma, Inc.
―
Lepu Biopharma Co. Ltd. Class H
―
Keymed Biosciences, Inc.
―
CARsgen Therapeutics Holdings Ltd.
―
Shandong Boan Biotechnology Company., Limited. Class H
―
Options Prices
Currently, No data available
---